{"id":"oral-steroid-predonisolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisolone enters cells and binds to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The drug is commonly used in oncology as an adjunctive agent to manage treatment-related inflammation and as part of combination chemotherapy regimens.","oneSentence":"Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:49.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment in cancer therapy to manage inflammation and side effects"},{"name":"Lymphoproliferative disorders"},{"name":"Autoimmune complications in cancer patients"}]},"trialDetails":[{"nctId":"NCT04498260","phase":"PHASE4","title":"Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2019-01-21","conditions":"Esophageal Stenosis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oral steroid - predonisolone","genericName":"Oral steroid - predonisolone","companyName":"Instituto do Cancer do Estado de São Paulo","companyId":"instituto-do-cancer-do-estado-de-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Adjunctive treatment in cancer therapy to manage inflammation and side effects, Lymphoproliferative disorders, Autoimmune complications in cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}